Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Post-HAART outcomes in pediatric populations: comparison of resource-limited and developed countries.

Peacock-Villada E, Richardson BA, John-Stewart GC.

Pediatrics. 2011 Feb;127(2):e423-41. doi: 10.1542/peds.2009-2701. Review.

PMID:
21262891
2.

Long-term effects of highly active antiretroviral therapy on CD4+ cell evolution among children and adolescents infected with HIV: 5 years and counting.

Patel K, HernĂ¡n MA, Williams PL, Seeger JD, McIntosh K, Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team..

Clin Infect Dis. 2008 Jun 1;46(11):1751-60. doi: 10.1086/587900.

PMID:
18426371
3.

Single-dose safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus type 1 (HIV-1) protease inhibitor, in HIV-infected children.

Yogev R, Kovacs A, Chadwick EG, Homans JD, Lou Y, Symonds WT.

Antimicrob Agents Chemother. 2005 Jan;49(1):336-41.

PMID:
15616313
4.

Pharmacokinetics of indinavir combined with low-dose ritonavir in human immunodeficiency virus type 1-infected children.

Bergshoeff AS, Fraaij PL, van Rossum AM, Verweel G, Wynne LH, Winchell GA, Leavitt RY, Nguyen BY, de Groot R, Burger DM.

Antimicrob Agents Chemother. 2004 May;48(5):1904-7.

PMID:
15105157
5.

Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children.

Burger DM, van Rossum AM, Hugen PW, Suur MH, Hartwig NG, Geelen SP, Scherpbier HJ, Hoetelmans RM, Vulto AG, de Groot R; Dutch Study Group for Children with HIV-1 Infection..

Antimicrob Agents Chemother. 2001 Mar;45(3):701-5.

PMID:
11181346
6.

Pharmacologic characteristics of indinavir, didanosine, and stavudine in human immunodeficiency virus-infected children receiving combination therapy.

Fletcher CV, Brundage RC, Remmel RP, Page LM, Weller D, Calles NR, Simon C, Kline MW.

Antimicrob Agents Chemother. 2000 Apr;44(4):1029-34.

PMID:
10722507
7.

Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.

Gatti G, Vigano' A, Sala N, Vella S, Bassetti M, Bassetti D, Principi N.

Antimicrob Agents Chemother. 2000 Mar;44(3):752-5.

PMID:
10681350
Items per page

Supplemental Content

Support Center